Nitrogen Bonded Directly To Ring Carbon Of The 1,3-diazine Ring Of The Quinazoline Ring System Patents (Class 514/266.4)
-
Patent number: 11692028Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions. The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of Marfan syndrome and related diseases, disorders and conditions.Type: GrantFiled: March 2, 2018Date of Patent: July 4, 2023Assignee: The Johns Hopkins UniversityInventors: Harry C. Dietz, Jefferson J. Doyle, Alexander J. Doyle
-
Patent number: 11673876Abstract: This disclosure is in the field of medicinal chemistry, and relates to a new class of small-molecules having the Formula I, or a pharmaceutically acceptable salt or solvate thereof, or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, wherein the variables Ring A, X, R1a, R1b, R2, R3, R4, m, n, and p are described herein, which function as dual inhibitors of EGFR proteins and PI3K proteins. The disclosure further relates to the use of the compounds described herein as therapeutics for the treatment of diseases and conditions mediated by EGFR proteins and/or PI3K proteins, such as cancer and other diseases.Type: GrantFiled: December 21, 2021Date of Patent: June 13, 2023Assignee: Mekanistic Therapeutics LLCInventors: Christopher E. Whitehead, Judith S. Leopold
-
Patent number: 11524009Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.Type: GrantFiled: October 30, 2018Date of Patent: December 13, 2022Assignee: Eisai R&D Management Co., Ltd.Inventors: Daniel Aird, Laura Corson, Ping Zhu, Markus Warmuth, Silvia Buonamici, Peter Gerard Smith, Peter Fekkes
-
Patent number: 11510912Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.Type: GrantFiled: April 14, 2020Date of Patent: November 29, 2022Assignee: Novartis AGInventors: Ha-Soon Choi, James Paul Lajiness, Srinivasa Reddy Natala, Bao Nguyen, Hank Michael James Petrassi, Zhicheng Wang
-
Patent number: 11446273Abstract: Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.Type: GrantFiled: December 20, 2018Date of Patent: September 20, 2022Assignee: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Yasuko Yamamoto, Takazumi Taniguchi
-
Patent number: 11225464Abstract: The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V and formula VI or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of gastrointestinal polyps or its associated complications.Type: GrantFiled: April 19, 2017Date of Patent: January 18, 2022Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 10953016Abstract: The present invention provides a formulation containing the compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or their crystals, with a light-stabilizing substance and a polymer, particularly with one or more of titanium oxide and talc used as the light-stabilizing substance, and hypromellose used as the polymer, which hardly increase the amount of the related substances, and the formulation is hardly colored under light irradiation.Type: GrantFiled: January 29, 2018Date of Patent: March 23, 2021Assignee: SHIONOGI & CO., LTD.Inventors: Reiji Yokoyama, Satoshi Sakuma, Shohei Aikawa, Hironori Tanaka
-
Patent number: 10947201Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.Type: GrantFiled: February 16, 2016Date of Patent: March 16, 2021Assignee: NEUPHARMA, INC.Inventors: Xiangping Qian, Yong-Liang Zhu
-
Patent number: 10829479Abstract: The invention concerns compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3 and R4 have any of the meanings hereinbefore defined in the description; process for their preparation; pharmaceutical compositions containing them and their use in treating KIT mediated diseases.Type: GrantFiled: March 5, 2019Date of Patent: November 10, 2020Assignee: AstraZeneca ABInventors: Jason Kettle, Stuart Pearson, Martin Packer, James Smith, Tudor Grecu
-
Patent number: 10766961Abstract: The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.Type: GrantFiled: August 11, 2015Date of Patent: September 8, 2020Assignee: ImClone LLCInventors: Paolo B. Abada, Shao-Chun Chang, Yanzhi Hsu, Ling Yang
-
Patent number: 10703746Abstract: Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.Type: GrantFiled: December 22, 2015Date of Patent: July 7, 2020Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: Matthew Brian Boxer, Jason Matthew Rohde, Rajan Pragani, Li Liu, Mindy Irene Emily Davis, Kyle Ryan Brimacombe, Min Shen, Anton Simeonov, Surendra Karavadhi, Daniel Jason Urban, Ajit Jadhav, Xiaodong Wang, Andrew Louis McIver
-
Patent number: 10689372Abstract: Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor.Type: GrantFiled: November 6, 2018Date of Patent: June 23, 2020Assignee: ARENA PHARMACEUTICALS, INC.Inventors: Thuy-Anh Tran, Jason B. Ibarra, Young-Jun Shin, Brett Ullman, Ning Zou, Xi Zeng
-
Patent number: 10556884Abstract: Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in a manner known per se.Type: GrantFiled: September 21, 2016Date of Patent: February 11, 2020Assignee: Syngenta Participations AGInventors: Andrew Edmunds, Pierre Joseph Marcel Jung, Michel Muehlebach, André Jeanguenat, Daniel Emery, Roger Graham Hall, Vikas Sikervar, Jagadish Pabba
-
Patent number: 10548898Abstract: Described herein are compounds of Formula (I) and tautomers and pharmaceutical salts thereof, compositions and formulations containing such compounds, and methods of using and making such compounds.Type: GrantFiled: January 4, 2019Date of Patent: February 4, 2020Assignees: Gilead Sciences Inc., Institute of Organic Chemistry and Biochemistry of the AS CR, V.V.I.Inventors: Ondrej Baszczynski, Milan Dejmek, Yunfeng Eric Hu, Petr Jansa, Eric Lansdon, Richard L. Mackman, Petr Simon
-
Patent number: 10322126Abstract: Disclosed are compositions including a solid dispersion comprising a dispersion polymer, a basic low-water solubility active, and an anionic counterion, as well as methods of making and using the compositions.Type: GrantFiled: August 21, 2017Date of Patent: June 18, 2019Assignee: Bend Research, Inc.Inventors: Warren K. Miller, Michael M. Morgen
-
Patent number: 9957237Abstract: Provided is a composition of N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(ethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide p-toluene sulfonate 1.5 hydrate ?-polymorph. The ?-polymorph has a stable form, a defined melting point, a good chemical stability, and a good endurance to high temperature and light irradiation, and is suitable for pharmaceutical use.Type: GrantFiled: December 22, 2015Date of Patent: May 1, 2018Assignee: SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD.Inventors: Tian Tang, Feng Jin, Yanqing Wang, Jing Wu, Xiarou Liu, Jing'an Yang, Hanlin Feng, Lin Yu
-
Patent number: 9840494Abstract: Disclosed are N-[4-(3-chloro-4-fluorophenylamino)-7-(2-methoxyethoxy) quinazolin-6-yl]-2 -[1-(2-methoxyethyl)piperidin-4-ylidene]acetamide and a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 12, 2014Date of Patent: December 12, 2017Assignee: Tianjin Hemay Oncology Pharmaceutical Co., Ltd.Inventors: Hesheng Zhang, Guanghuai Zeng, Yingwei Chen
-
Patent number: 9750741Abstract: Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.Type: GrantFiled: March 17, 2014Date of Patent: September 5, 2017Assignees: The Translational Genomics Research Institute, MAYO Foundation for Medical Education and ResearchInventors: Mitesh Jivraj Borad, David Craig, John Carpten
-
Patent number: 9717792Abstract: Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or etiolates.Type: GrantFiled: February 1, 2013Date of Patent: August 1, 2017Assignee: The University of British ColumbiaInventors: Martin E. Gleave, Amina Zoubeidi, Masafumi Kumano
-
Patent number: 9394261Abstract: A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.Type: GrantFiled: February 25, 2015Date of Patent: July 19, 2016Assignees: NATIONAL YANG-MING UNIVERSITY, NATIONAL TAIWAN UNIVERSITYInventors: Chung-Wai Shiau, Kuen-Feng Chen
-
Patent number: 9388160Abstract: The present invention is directed to novel quinazolines, their derivatives, pharmaceutically acceptable salts, solvates, prodrug, stereoisomer, tautomer, metabolite and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are expected to be useful for the treatment of protein kinases mediated diseases and conditions.Type: GrantFiled: October 12, 2012Date of Patent: July 12, 2016Assignee: Teligene LtdInventor: Dawei Zhang
-
Patent number: 9359349Abstract: The present invention provides compounds of Formula I that modulate PI3 kinase activity and methods of treatment of diseases and conditions associated with PI3 kinase activity.Type: GrantFiled: September 19, 2014Date of Patent: June 7, 2016Assignee: INTELLIKINE LLCInventors: Pingda Ren, Yi Liu, Troy Edward Wilson
-
Patent number: 9187462Abstract: Compounds having the formula (I) wherein R1, R2, R3 and Ar as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.Type: GrantFiled: August 3, 2012Date of Patent: November 17, 2015Assignees: Array BioPharma Inc., Genentech, Inc.Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Ferdinand Garrey, John Gaudino, Lewis Gazzard, Robert J. Kaus, Samuel Kintz, Peter J. Mohr, David A. Moreno, Jacob Schwarz, Christopher S. Siedem, Eli M. Wallace
-
Patent number: 9150549Abstract: The invention provides A combination of, a) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.Type: GrantFiled: March 30, 2012Date of Patent: October 6, 2015Assignee: Genentech, Inc.Inventors: Michelle Nannini, Deepak Sampath
-
Patent number: 9073985Abstract: Methods and products for treating proliferative diseases, and wounds, using as a pharmacon an autophagy inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In some embodiments, the invention combines a 4-aminoquinoline, exemplified by chloroquine, with a glycolytic inhibitor, exemplified by 2-deoxy-D-glucose and anti-VEGF antibodies. The systems and methods of the invention may be used to treat drug-resistant or multi-drug resistant cancers.Type: GrantFiled: July 14, 2009Date of Patent: July 7, 2015Assignee: The Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell, Susannah K. Rogers
-
Patent number: 9067897Abstract: 2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA).Type: GrantFiled: January 20, 2011Date of Patent: June 30, 2015Assignee: Families of Spinal Muscular AtrophyInventors: Jasbir Singh, Mark E. Gurney
-
Publication number: 20150141442Abstract: Certain chemical entities that modulate PI3 kinase activity, and chemical entities, pharmaceutical compositions, and methods of treatments of diseases and conditions associated with PB kinase activity are described.Type: ApplicationFiled: September 19, 2014Publication date: May 21, 2015Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson
-
Publication number: 20150133476Abstract: The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.Type: ApplicationFiled: November 18, 2014Publication date: May 14, 2015Inventors: Jianhui Guo, Yong Jiang
-
Publication number: 20150126537Abstract: The present invention is directed to novel bicyclic compounds, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities and are useful for the treatment of protein kinases mediated diseases and conditions. Novel bicyclic compounds disclosed herein include quinazolines and quinolines.Type: ApplicationFiled: May 13, 2013Publication date: May 7, 2015Inventor: Dawei Zhang
-
Patent number: 9023354Abstract: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.Type: GrantFiled: January 16, 2014Date of Patent: May 5, 2015Inventor: Joseph P. Errico
-
Publication number: 20150119405Abstract: Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.Type: ApplicationFiled: October 23, 2014Publication date: April 30, 2015Applicant: BLUEPRINT MEDICINES CORPORATIONInventors: Neil Bifulco, Jr., Lucian V. DiPietro, Brian L. Hodous, Chandrasekhar V. Miduturu
-
Publication number: 20150112116Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.Type: ApplicationFiled: October 24, 2013Publication date: April 23, 2015Inventor: STEVEN HOFFMAN
-
Publication number: 20150111907Abstract: The invention relates to methods of predicting the clinical outcome of brain cancer patients based on the LOH levels of the PTEN gene and on the expression levels or the polysomy/amplification levels of EGFR gene in a sample from said patients.Type: ApplicationFiled: December 23, 2014Publication date: April 23, 2015Inventors: Michael J. DONOVAN, Anna Colomer Valero, Nadina Erill Sagales, Isidre Ferrer Abinzanda, Susana Boluda Casas
-
Publication number: 20150111847Abstract: The present invention relates to processes for the preparation of erlotinib and salts and polymorphs thereof preparable by said processes, to medical uses of said erlotinib, salts and polymorphs, and to pharmaceutical compositions comprising the same.Type: ApplicationFiled: January 6, 2015Publication date: April 23, 2015Applicant: GENERICS [UK] LIMITEDInventors: Vinayak Govind Gore, Anilkumar Tripathi, Madhav Jadhav
-
Publication number: 20150105412Abstract: Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.Type: ApplicationFiled: December 16, 2014Publication date: April 16, 2015Inventor: Joseph P. Errico
-
Patent number: 9006257Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.Type: GrantFiled: February 7, 2013Date of Patent: April 14, 2015Assignee: Glenmark Pharmaceuticals S.A.Inventors: Laxmikant Atmaram Gharat, Abhisek Banerjee, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
-
Publication number: 20150094275Abstract: The present invention provides novel heteroaryl compounds having a pyrimidine-containing core that is linked to a 4-trifluoromethoxyphenyl group via an amine linker. Such compounds are useful for the treatment of cancers.Type: ApplicationFiled: November 13, 2014Publication date: April 2, 2015Applicants: THE SCRIPPS RESEARCH INSTITUTE, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
-
Publication number: 20150086543Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.Type: ApplicationFiled: November 24, 2014Publication date: March 26, 2015Applicant: GENENTECH, INC.Inventors: Thomas E. Januario, David Shames
-
Publication number: 20150079079Abstract: The present invention provides compositions and methods of use in the treatment/prevention of chlamydial infection and/or diseases and disorders associated with chlamydial infection in a subject.Type: ApplicationFiled: September 11, 2014Publication date: March 19, 2015Inventors: Allen W. Tsang, Cristina M. Furdui
-
Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof
Publication number: 20150079028Abstract: Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.Type: ApplicationFiled: August 5, 2013Publication date: March 19, 2015Applicant: SUNSHINE LAKE PHARMA CO., LTDInventors: Yingjun Zhang, Jaincun Zhang, Hongming Xie, Qingyun Ren, Yumei Tan, Huichao Luo -
Publication number: 20150080409Abstract: Embodiments of the present disclosure, in one aspect, relate to a 2,4-diaminoquinazoline compound, pharmaceutical compositions including a 2,4-diaminoquinazoline compound, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.Type: ApplicationFiled: October 31, 2014Publication date: March 19, 2015Applicant: University of South Florida (A Florida Non-Profit Corporation)Inventors: Roman Manetsch, Lindsey Neil Shaw, Kurt Steven Van Horn, Whittney Nicole Burda
-
Patent number: 8980321Abstract: A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.Type: GrantFiled: July 14, 2014Date of Patent: March 17, 2015Assignee: Bend Research, Inc.Inventors: William J. Curatolo, Ravi M. Shanker, Walter C. Babcock, Dwayne T. Friesen, James A. S. Nightingale, Douglas A. Lorenz
-
Publication number: 20150071919Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Patients to be treated include those that have been treated with Tarceva or other therapeutic compounds and relapsed or are resistant to treatment. The compounds described herein may exhibit a synergistic effect when administered with another agent.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Thomas F. WHITE, Dan HOTH
-
Publication number: 20150065526Abstract: This disclosure relates to methods of treating cancer comprising administering an effective amount of a STAT3 inhibitor, prodrugs, or derivatives thereof, in combinations with an EGFR tyrosine kinase inhibitors, prodrugs, or derivatives thereof, to a subject in need thereof. In certain embodiments, the STAT3 inhibitor is niclosamide or salt thereof. In certain embodiments, the EGFR tyrosine kinase inhibitor is erlotinib or salt thereof.Type: ApplicationFiled: September 5, 2014Publication date: March 5, 2015Inventors: Xingming Deng, Rui Li, Fadio R. Khuri, Taofeek Kunle Owonikoko
-
Publication number: 20150057275Abstract: This invention relates generally to methods and materials for rapid detection of mutations for tumor genotyping.Type: ApplicationFiled: September 2, 2014Publication date: February 26, 2015Inventors: Dora Dias-Santagata, Anthony John Iafrate
-
Publication number: 20150057267Abstract: The invention provides a method for treating viral infections and coinfections through the use of inhibitory agents that prevent a unique viral structural protein motifs from binding to host proteins from the clathrin adaptor proteins family and subsequently preventing viral replication.Type: ApplicationFiled: December 6, 2012Publication date: February 26, 2015Applicant: The Board of Trustees of the Leland Stanford Junior universityInventors: Shirit Einav, Rina Barouch-Bentov, Gregory Neveu, Amotz Zivav
-
Publication number: 20150056193Abstract: The present disclosure provides methods of that include detecting in a biological sample from a patient having or suspected of having cancer the presence of a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and detecting in the biological sample the presence of a mutant EGFR polypeptide or a polynucleotide encoding the same. In some aspects, the disclosure provides methods of treating a patient for cancer that include determining that a biological sample from a tumor in the patient includes a polypeptide having ROS1 kinase activity or a polynucleotide encoding the same and a mutant EGFR polypeptide or a polynucleotide encoding the same and administering to the patient a therapeutically effective amount of a ROS1 inhibitor and an EGFR inhibitor, thereby treating the patient for cancer.Type: ApplicationFiled: April 18, 2013Publication date: February 26, 2015Applicant: CELL SIGNALING TECHNOLOGY, INC.Inventors: Katherine Eleanor Crosby, Victoria McGuinness Rimkunas, Matthew Ren Silver, Herbert Haack
-
Publication number: 20150050239Abstract: The present invention provides novel substituted pyrazolone compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: July 19, 2013Publication date: February 19, 2015Applicants: Calitor Sciences, LLC, Sunshine Lake Pharma Co., Ltd.Inventors: Ning Xi, Yanjun Wu, Min Liao, Yanming Feng
-
Publication number: 20150045363Abstract: Hedgehog pathway inhibitors, such as small molecules, are used to prevent, slow, block the formation of cartilage tumors as well as exostosis or enchondromas.Type: ApplicationFiled: March 14, 2013Publication date: February 12, 2015Inventors: Wentian Yang, Benjamin G. Neel
-
Publication number: 20150038520Abstract: The invention relates to methods for determining the clinical outcome of patients suffering lung cancer and being under treatment with an EGFR inhibitor. The methods are based on the detection of the presence of mutations in the EGFR gene conferring resistance to inhibitors of the EGFR tyrosine kinase activity, wherein the appearance of said mutations in the biofluid of the patient is indicative of a high probability that the patient suffers a relapse of the disease. The invention also provides therapeutic methods for said patients.Type: ApplicationFiled: December 22, 2011Publication date: February 5, 2015Applicant: Pangaea Biotech S.L.Inventors: Miguel Tarón Roca, Rafael Rosell Costa